ViiV Healthcare
Presencia
GSK es una de las ...
- Forbes Global 2000 (#187);
- Fortune 500 Europe (#81);
- FTSE 350;
- Global Fortune 500 (#343);
- Stoxx 600.
GSK es una empresa que cotiza bajo el símbolo de cotización GSK (GB).
GSK tiene presencia directa en 21 países.GSK posee 22 subsidiarias incluyendo GSK ANZ, GSK APAC y GSK Austria.
Fusión, adquisición y financiación con participación de GSK.
- GSK has announced the acquisition of Aiolos Bio (publicado el 12 de enero de 2024).
- GSK has announced the acquisition of Bellus Health (publicado el 19 de abril de 2023).
- GSK has announced the acquisition of Affinivax (publicado el 1 de junio de 2022).
Ejecutivos
Ver el organigrama con sus 22 ejecutivos principales
Biografías más buscadas en ViiV Healthcare
- Deborah Waterhouse, Chief Executive Officer and Director
- Regis Simard, Director
- David Redfern, Chairman of the Board
Recientes movimientos de ejecutivos en GSK
- Jeannie Lee se incorporará a la empresa como Non-Executive Director el 4 de mar.. de 2024 (noticia publicada el 29 de febrero de 2024).
- Wendy Becker se incorporará a la empresa como Non-Executive Director el 1 de oct.. de 2023 (noticia publicada el 28 de septiembre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en ViiV Healthcare.
Farmacia
GSK tiene 1.867 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
- Frontier Medicines acaba de anunciar una recaudación de fondos de 80 millones de dólares. (publicado el 27 de febrero de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de ViiV Healthcare
- ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil
- ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
- ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices
- ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
- ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
- ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
- ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic
- Welsh Rugby star Gareth Thomas and ViiV Healthcare launch Tackle HIV campaign to address public misunderstanding and stigma associated with HIV
- Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
- ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic
- View more press releases Close
Redes sociales sobre ViiV Healthcare
- ViiV Healthcare en Wikipedia, Google News y Yahoo Finance
- ViiV Healthcare en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos David Redfern 
Llame a ViiV Healthcare al +44 792...
